Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation

Giovanni Tuccari, Antonio Ieni, Valeria Barresi, Rosario Caltabiano, Pio Zeppa, Rachele Del Sordo, Daniela Cabibi, Salvatore Lanzafame, Angelo Sidoni, Vito Franco, Anna Maria Cascone
  • OncoTargets and Therapy, July 2014, Dove Medical Press
  • DOI: 10.2147/ott.s65294

HER2 immunohistochemical evaluation in lymph node metastases

What is it about?

We have reported the discordance in immunoexpression of HER2 in primary breast carcinoma and synchronous axillary lymph node metastases.

Why is it important?

The positivity in lymph node metastases may allow the possibility of target therapy.

Perspectives

Dr Rosario Caltabiano
Department G.F. Ingrassia Section of Anatomic Pathology University of Catania

Improve overall survival in breast cancer patients

open access logoRead Publication

http://dx.doi.org/10.2147/ott.s65294

The following have contributed to this page: Professor Giovanni Tuccari, Dr Rosario Caltabiano, and Professor daniela cabibi